Form 8-K - Current report:
SEC Accession No. 0001493152-24-043558
Filing Date
2024-11-04
Accepted
2024-11-04 17:24:49
Documents
24
Period of Report
2024-11-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38648
2 ex99-1.htm EX-99.1 10936
3 ex99-1_001.jpg GRAPHIC 195059
4 ex99-1_002.jpg GRAPHIC 348129
5 ex99-1_003.jpg GRAPHIC 202857
6 ex99-1_004.jpg GRAPHIC 279042
7 ex99-1_005.jpg GRAPHIC 273552
8 ex99-1_006.jpg GRAPHIC 278506
9 ex99-1_007.jpg GRAPHIC 271582
10 ex99-1_008.jpg GRAPHIC 210881
11 ex99-1_009.jpg GRAPHIC 223609
12 ex99-1_010.jpg GRAPHIC 291406
  Complete submission text file 0001493152-24-043558.txt   3769618

Data Files

Seq Description Document Type Size
13 XBRL SCHEMA FILE ibo-20241104.xsd EX-101.SCH 3033
14 XBRL LABEL FILE ibo-20241104_lab.xml EX-101.LAB 34240
15 XBRL PRESENTATION FILE ibo-20241104_pre.xml EX-101.PRE 24178
26 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3494
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42212 | Film No.: 241424811
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)